Profile data is unavailable for this security.
About the company
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
- Revenue in USD (TTM)0.00
- Net income in USD-51.23m
- Incorporated2011
- Employees--
- LocationSkye Bioscience Inc11250 EL CAMINO REAL, SUITE 100SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 410-0266
- Fax+1 (775) 782-2611
- Websitehttps://skyebioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.36m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 21.57m | 7.00 | -- | 2.45 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.78m | 7.00 | -- | 0.7632 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.84m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 21.87m | 34.00 | -- | 2.69 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 22.08m | 1.00 | -- | 0.7388 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 22.67m | 66.00 | -- | -- | -- | 2.43 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 22.73m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
| LAMY | 0.00 | 106.70k | 23.10m | -- | 24.05 | -- | 190.26 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.20m | -- | -- | 0.6831 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 23.84m | 5.00 | -- | 1.30 | -- | 5.08 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -3.00k | 24.02m | 5.00 | 0.2054 | -- | 308.00 | -- | 4.87 | 4.87 | 0.00 | -1.71 | 0.00 | -- | -- | 0.00 | -0.0471 | -- | -- | -- | -- | -- | -- | -- | -- | -5.95 | -- | -- | -- | -- | 110.92 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 24.14m | 41.00 | -- | 1.80 | -- | 3.40 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| IGC Pharma Inc | 1.11m | -6.45m | 24.53m | 70.00 | -- | 2.91 | -- | 22.18 | -0.078 | -0.078 | 0.0134 | 0.088 | 0.11 | 0.5489 | 26.02 | 15,800.00 | -64.10 | -51.04 | -81.62 | -56.88 | 46.20 | 43.57 | -582.82 | -1,150.02 | 0.889 | -- | 0.0165 | -- | -5.50 | -20.77 | 45.22 | -- | -35.93 | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.30m | 64.00 | -- | 0.2296 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| Rallybio Corp | 674.00k | -14.17m | 25.45m | 15.00 | -- | 0.4008 | -- | 37.76 | -2.55 | -2.55 | 0.1203 | 12.02 | 0.0092 | -- | -- | 26,960.00 | -19.32 | -40.97 | -21.16 | -43.42 | -- | -- | -2,102.37 | -42,838.52 | -- | -- | 0.00 | -- | -- | -- | 22.52 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Skye Bioscience Inc's reporting currency: US Dollar USD
18.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 1.45m | 4.53% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2025 | 1.19m | 3.70% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 774.00k | 2.41% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 620.40k | 1.94% |
| Sphera Funds Management Ltd.as of 30 Sep 2025 | 478.93k | 1.49% |
| Millennium Management LLCas of 30 Sep 2025 | 402.38k | 1.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 278.45k | 0.87% |
| Global X Management Co. LLCas of 30 Sep 2025 | 269.73k | 0.84% |
| Platinum Investment Management Ltd.as of 31 Dec 2025 | 233.10k | 0.73% |
| Geode Capital Management LLCas of 31 Dec 2025 | 210.15k | 0.66% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
